依达拉奉右莰醇注射用浓溶液联合丁苯酞氯化钠注射液治疗高龄前循环急性脑梗死患者的效果及对预后的影响

Efficacy of edaravone dexborneol concentrated solution combined with butylphthalide sodium chloride injection in the treatment of elderly patients with acute anterior circulation infarction and its impact on prognosis

摘要:

目的 探讨依达拉奉右莰醇注射用浓溶液联合丁苯酞氯化钠注射液治疗高龄前循环急性脑梗死患者的效果及对预后的影响。方法 选取2020年3月—2022年8月在联勤保障部队第904医院就诊的82例高龄前循环急性脑梗死患者，以随机数字表法将患者分成对照组、研究组，各41例。两组均接受基础治疗，对照组在此基础上采用丁苯酞氯化钠注射液治疗，研究组在对照组基础上采用依达拉奉右莰醇注射用浓溶液治疗。两组均治疗14 d。对比两组神经功能、临床疗效、血管内皮功能、血液流变学及不良反应，随访3个月，对比两组短期预后。结果 研究组治疗前后神经元特异性烯醇化酶、美国国立卫生院神经功能缺损评分的差值均大于对照组（P < 0.05）。研究组总有效率高于对照组（P < 0.05）。研究组治疗前后VEGF水平的差值大于对照组（P < 0.05）。研究组治疗前后红细胞压积、血小板聚集率的差值均大于对照组（P < 0.05）。研究组与对照组总不良反应发生率比较，差异无统计学意义（P > 0.05）。研究组治疗前后改良Rankin量表评分的差值大于对照组（P < 0.05）。研究组与对照组病死率比较，差异无统计学意义（P > 0.05）。结论 依达拉奉右莰醇注射用浓溶液联合丁苯酞氯化钠注射液可改善高龄前循环急性脑梗死患者血管内皮功能、血液流变学、神经功能，疗效显著，安全可靠，且短期预后良好。

Abstract:

Objective To investigate the efficacy of edaravone dexborneol concentrated solution combined with butylphthalide sodium chloride injection in the treatment of elderly patients with acute anterior circulation infarction and its impact on prognosis.Methods Eighty-two elderly patients with acute anterior circulation infarction in our hospital from March 2020 to August 2022 were selected and divided into the control group (41 patients) and the study group (41 patients) by the random number table method. Both groups received standard treatment. On this basis, the control group was treated with butylphthalide sodium chloride injection, while the study group received additional treatment with edaravone dexborneol concentrated solution. Both groups were treated for 14 days. Neurological function, clinical efficacy, vascular endothelial function, hemorheology and adverse effects were compared between the two groups, and the short-term prognosis of the two groups was compared after a 3-month follow-up.Results The differences in the NSE level and NIHSS score before and after treatment in the study group were higher than those in the control group (P < 0.05). The overall effective rate of the study group was higher than that of the control group (P < 0.05). The difference in the VEGF level before and after treatment in the study group was higher than that in the control group (P < 0.05). The differences in the hematocrit and the platelet aggregation rate before and after treatment in the study group were higher than those in the control group (P < 0.05). There was no difference in the overall incidence of adverse reactions between the study group and the control group (P > 0.05). The difference in the modified Rankin scale scores before and after treatment in the study group was higher than that in the control group (P < 0.05). The difference in the mortality rate between the study group and the control group was not statistically significant (P > 0.05).Conclusion Edaravone dexborneol concentrated solution combined with butylphthalide sodium chloride injection can improve vascular endothelial function, hemorheology and neurological function in elderly patients with acute anterior circulation infarction. It demonstrates significant efficacy, good safety, and favorable short-term prognosis.